Promising Cancer Vaccine Shows Potential to Reduce Recurrence
A new cancer vaccine is offering hope in the fight against certain types of cancer. Researchers from the UCLA Health Jonsson Comprehensive Cancer Center tested an experimental vaccine called ELI-002 2P on 25 patients who had previously been treated for pancreatic and colorectal cancer. The trial focused on patients who had undergone surgery to remove tumors but still had traces of cancerous DNA, indicating a high chance of recurrence.
Studies have found that over 80% of pancreatic cancer patients see their cancer return after surgery, often within the first year. For colorectal cancer, the recurrence rate ranges from 30% to 50%, particularly in the first two years following surgery.
The vaccine specifically targets mutations in the KRAS gene, which are responsible for about half of colorectal cancers and over 90% of pancreatic cancers. It is administered through a series of injections to stimulate an immune response.
Out of the 25 patients, 21 developed what are called “KRAS-specific T cells,” suggesting a strong immune response. Those with a more robust immune reaction enjoyed longer periods without cancer than those with weaker responses.
In a promising turn of events, three colorectal and three pancreatic cancer patients saw all disease biomarkers disappear following vaccination. Many of those who showed the best immune response remained free of cancer nearly 20 months after receiving the vaccine.
Dr. Zev Wainberg, a professor of medicine at UCLA and one of the study’s authors, expressed optimism about the findings. He noted that patients who developed strong immune responses remained disease-free longer than expected.
The study revealed that about 67% of participants also showed immune responses to additional tumor mutations, indicating the vaccine’s potential for broader anti-cancer effects.
One of the key benefits of ELI-002 2P is that it is an “off-the-shelf” vaccine, making it easier to produce and administer without needing individual customization for each patient. Dr. Wainberg highlighted that this vaccine can effectively train the immune system to recognize and attack cancer-causing mutations.
The team is already preparing for a phase 2 study to test an updated version of the vaccine that will tackle a wider range of KRAS mutations. This next iteration, known as ELI-002 7P, aims to enhance the vaccine’s effectiveness.
The research was funded and supported by Elicio Therapeutics and collaborated with other renowned cancer centers, including MD Anderson and Memorial Sloan Kettering.
Health experts are enthusiastic about the potential of targeted therapies like this vaccine to change cancer treatment. Solid tumors can be particularly tough to treat, but advancements like ELI-002 2P may offer new strategies for patients battling severe forms of cancer.
